Mentoring clinician scientists in patient-oriented substance use disorder research

项目摘要/摘要： 物质使用障碍很普遍，与严重的发病率有关，是 可预防的死亡。尽管提供者拥有许多基于证据的治疗方法，如 治疗倾向于近乎中等的效果规模，使一些患者成为无应答者。工作是需要的 以改进现有的或开发具有更大疗效的新疗法。这是职业生涯中期的调查员奖 以患者为中心的研究将使Joseph Sakai医学博士从临床和行政职责中解脱出来 继续职业发展活动，扩大他的实验室在神经调节和成瘾方面的工作，并 为早期职业调查人员提供高质量的指导。酒井博士参与了几项针对 酒精使用障碍的治疗，并联系PI获得UG3奖，以测试大脑深部刺激 使用交叉设计治疗难治性甲基苯丙胺使用障碍。这个职业生涯中期奖，如果 资金将使酒井博士的实验室能够测试加速经颅磁感应的安全性和可行性 甲基苯丙胺使用障碍刺激治疗方案。此外，这项试验将允许有效大小 为未来的审判提供动力的估计。每个项目都为学员的参与和指导提供了重要机会 如申请表中所述。酒井博士是CU-Path居民研究轨道的负责人，该轨道寻求 在精神病学系培养注重研究的内科科学家。因为那个节目 成功后，CU获得了R25，以支持通过NRMP每年跟踪和匹配2名居民 (酒井MPI)。酒井博士还积极参加了DPRG T32博士后研究奖学金培训 计划于2022年续订(酒井是副主任，是2名博士后的主要导师 计划)。因此，酒井博士正式确定了主要部门指导计划中的角色，具体包括 专注于内科科学家；所有计划都强调并重视招聘有背景的个人 在医学界的代表性不足。

PROJECT SUMMARY/ABSTRACT: Substance use disorders are prevalent, are associated with serious morbidity and are common causes of preventable death. Although providers have at their disposal a number of evidence-based treatments, such treatments tend to be of near-moderate effect size, leaving some patients as non-responders. Work is needed to enhance existing or develop new treatments with higher effects sizes. This mid-career investigator award in patient-oriented research would enable Joseph Sakai, MD release from clinical and administrative duties to allow continued career development activities, to expand his lab’s work on neuromodulation and addiction and to provide high-quality mentorship to early career investigators. Dr. Sakai is involved in several medication trials for the treatment of alcohol use disorder and is contact PI for a UG3 award to test deep brain stimulation for treatment refractory methamphetamine use disorder utilizing a crossover design. This mid-career award, if funded, would allow Dr. Sakai’s lab to test the safety and feasibility of an accelerated transcranial magnetic stimulation treatment protocol for methamphetamine use disorder. In addition, this trial would allow effect size estimation to power a future trial. Each project allows key opportunities for trainee participation and mentorship as described in the application. Dr. Sakai is director of the CU-Pathways resident research track, which seeks to develop research-oriented physician scientists in the Department of Psychiatry. Because of that program’s successes, CU was awarded an R25 to support that track and match 2 residents per year through the NRMP (Sakai MPI). Dr. Sakai has also been very active with the DPRG T32 post-doctoral research fellowship training program which was renewed in 2022 (Sakai is associate director, and is primary mentor for 2 post-docs in that program). Thus, Dr. Sakai has formalized roles within major departmental mentorship programs with a specific focus on physician scientists; all programs emphasize and value recruitment of individuals from backgrounds under-represented in medicine.